Literature DB >> 9004450

Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: expression levels and immune response.

R Anderson1, G Dougan, M Roberts.   

Abstract

Pertactin/P.69, a surface-associated polypeptide antigen of Bordetella pertussis, was expressed in a Salmonella typhimurium aroA aroD vaccine strain, BRD509, using different expression systems, and the immune response in mice against these constructs was compared. Initially, Pertactin/P.69 was expressed on the surface of BRD509 from a single copy of the gene encoding the antigen localized on the Salmonella chromosome. As previously shown, secretory and humoral antibody responses could not be detected following multiple immunization with this strain (BRD640). However, a strong anti-Pertactin/P.69 proliferative response was observed in murine splenocytes following a single oral dose with BRD640. The stimulated splenocytes secreted interferon-gamma but not interleukin-5, indicating that BRD640 induced a Th1 type T-helper response against Pertactin/P.69. We wished to construct a vaccine strain that might induce secretory and humoral responses against Pertactin/P.69 as well as a cell-mediated immune response. Consequently, Pertactin/P.69 was expressed at high levels in the cytoplasm of BRD509 under the control of the inducible nirB promoter from a ColE1-based replicon. Anti-Pertactin/P.69 immune responses were not observed following immunization of BALB/c mice with this strain (BRD975). Priming of the immune system against Pertactin/P.69 was, however, observed following oral immunization with BRD975 and boosting subcutaneously with purified Pertactin/P.69 antigen. The major anti-Pertactin/P.69 IgG subclass detected in boosted mice was IgG2a; thus, as BRD640, BRD975 appeared to induce a Th1 type T-helper response against Pertactin/P.69.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9004450     DOI: 10.1016/s0264-410x(96)00036-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

Authors:  C Jespersgaard; P Zhang; G Hajishengallis; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity.

Authors:  Shifeng Wang; Yuhua Li; Giorgio Scarpellini; Wei Kong; HuoYing Shi; Chang-Ho Baek; Bronwyn Gunn; Soo-Young Wanda; Kenneth L Roland; Xin Zhang; Patti Senechal-Willis; Roy Curtiss
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

3.  Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis.

Authors:  Beatriz del Rio; Jesus Lajara Fuente; Vera Neves; Raymond Dattwyler; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  Vaccine       Date:  2010-08-08       Impact factor: 3.641

4.  Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses.

Authors:  D Bumann
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  Immune response to Lactobacillus plantarum expressing Borrelia burgdorferi OspA is modulated by the lipid modification of the antigen.

Authors:  Beatriz del Rio; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

6.  Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease.

Authors:  Beatriz del Rio; Raymond J Dattwyler; Miguel Aroso; Vera Neves; Luciana Meirelles; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

7.  Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters.

Authors:  M Roberts; J Li; A Bacon; S Chatfield
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.

Authors:  S J Ward; G Douce; D Figueiredo; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

9.  Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium.

Authors:  S J Dunstan; C P Simmons; R A Strugnell
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

10.  Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.

Authors:  Violaine Dubois; Camille Locht
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.